Abstract:Annexin A1 (ANXA1) is a calcium-binding protein involved in arachidonic acid metabolism and epidermal growth factor receptor tyrosine kinase pathway. ANXA1 has been implicated in early squamous cell carcinogenesis of esophagus and correlates with degree of tumor differentiation. Our goal was to evaluate ANXA1 expression its correlation with different chemoradiation therapy (CRT) sensitivity and determine its prognostic significance in esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was used to assay the expression of ANXA1 in 60 patients (14 stage II, 6 stage III, and 40 stage IV) who underwent concurrent CRT from August 2007 to June 2011, and the clinical stage was determined according to the International Union against Cancer (UICC) Tumor-node-metastasis (TNM) 2002 classification. ANAX1 expression level was classified as positive (≥5% of tumor cells with cytoplasmic staining), negative (<5% of tumor cells with cytoplasmic staining), or negative; and was correlated with clinicopathologic features and patients' outcomes. The tissues were classified into responders group (completely remission, CR) and non- responders group (stable disease, SD) by endoscopy, according to the WHO Response Evaluation Criteria in Solid Tumors. The total positive expression rates of ANX A1 was 55.0% (33 of 60). Sixty patients were evaluable for response. There were 11 (18.4%) complete remission, 20 (33.3%) partial remission, 20 (33.3%) stable disease, and 9 (15.0%) progression disease. the positive expression rate of ANX A1 in responders was 72.7% (8 of 11), while 45.0% (9 of 20) in non-responders (p > 0.05). The expression of ANX A1 was not significantly correlated with patients’ age, gender, tumor location, tumor differentiation grade, T stage, N stage and clinical TNM stage (p > 0.05). In univariate analysis, overall survival correlated significantly with tumor differentiation grade (p = 0.004), short-term effect (p < 0.001, TNM stage (p = 0.039), Karnofsky performance status (p = 0.001) and ANXA1 expression (p = 0.050). Subgroup analysis for patients with stage IV, Patient with negative ANX A1 (n = 19) had significantly shorter median survival times than those with positive ANXA1 (n = 21) (11.4 months vs 13.1 months, p = 0.039). Our results indicate that positive ANXA1 expression is frequent in esophageal squamous cell carcinoma. The expression of ANX A1 was not associated with chemoradiation therapy sensitivity. However, it maybe serves as a novel prognostic biomarker for ESCC.

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

Annexin I and Tumor

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Annexin-1 Downregulation is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Tissue Microarray Analysis Reveals Strong Clinical Evidence for a Close Association Between Loss of Annexin A1 Expression and Nodal Metastasis in Gastric Cancer

Nuclear Localization of Annexin A1 Correlates with Advanced Disease and Peritoneal Dissemination in Patients with Gastric Carcinoma

Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer

Annexin A6 is down-regulated through promoter methylation in gastric cancer.

Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway

Expression and significance of ANXA1 mRNA in chronic gastritis and gastric cancer

Expression of Annexin A5 is Associated with Higher Tumor Stage and Poor Prognosis in Colorectal Adenocarcinomas.

[Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder].

ANXA2 regulates the behavior of SGC-7901 cells.

The Negative Expression of Annexin A1 in Esophageal Squamous Cell Carcinoma is Associated with Poor Outcome

Annexin A9 promotes cell proliferation by regulating the Wnt signaling pathway in colorectal cancer

Annexin A4 and cancer

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

Decreased Expression of Annexin A1 During the Progression of Cervical Neoplasia

Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma

Annexin A2 in Tumors of the Gastrointestinal Tract, Liver, and Pancreas

Annexin A2 is Implicated in Multi-Drug-resistance in Gastric Cancer Through P38mapk and AKT Pathway.